RestorGenex To Present At The American Association for Cancer Research Conference On Targeting The PI3K-MTOR Network In Cancer

RestorGenex Corporation (OTCQB:RESX), a specialty biopharmaceutical company initially focused on developing products for oncology, dermatology, ophthalmology and women’s health, today announced that David Sherris, Ph.D., RestorGenex’s chief scientific officer, will present scientific data on the Company’s proprietary RES-529 program in oncology. Dr. Sherris’ presentation at the American Association for Cancer Research Conference on Targeting the PI3K-mTOR Network in Cancer is scheduled for Monday, September 15, 2014 at 4:30 pm (EST) at the Sheraton Philadelphia Downtown Hotel, Philadelphia, Pennsylvania.

Help employers find you! Check out all the jobs and post your resume.